<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1996-11-20" id="root" itemid="203717" xml:lang="en">
<title>USA: RESEARCH ALERT - UroQuest, ADAC rated buys.</title>
<headline>RESEARCH ALERT - UroQuest, ADAC rated buys.</headline>
<text>
<p>-- Dillon, Read &amp; Co said analysts Raul Esquivel and Matthew Dodds initiated coverage of UroQuest Medical Inc and ADAC Laboratories with buy ratings.</p>
<p>-- The analysts put a one-year price target of $18-$20 per share on UroQuest, which makes products used to diagnose and manage urological disorders.</p>
<p>-- Dillon, Read was lead underwriter for Uroquest's October initial public offering at $6 a share. Shares were trading flat Wednesday at six.</p>
<p>-- The analysts put a one-year price target of $24-$26 on ADAC, a nuclear medicine company. It was up 1/2 at 19-7/8.</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1996-11-20" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>